Senzime (SEZI) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Oct, 2026Executive summary
Q3 net sales rose 14% reported and 12% currency-adjusted to SEK 30.099m; disposable sensor sales grew 43% across the US, Europe and Rest of World.
Gross margin reached 74.0%, EBITDA improved to SEK -8.026m and operating expenses fell 15% YoY.
Positive cash flow remains targeted within Q4 2026, though ambitious full-year sales growth targets remain challenging.
Financial highlights
Q1–Q3 sales were SEK 78.002m, up 3% reported and 7% currency-adjusted.
Q3 operating profit was SEK -14.232m vs SEK -25.425m; net loss was SEK 11.254m vs SEK 25.534m, with EPS of SEK -0.07 vs SEK -0.16.
Q3 cash flow improved to SEK -8.7m from SEK -28.3m; operating cash flow was SEK -6.3m vs SEK -23.8m.
Q1–Q3 EBITDA was SEK -45.495m vs SEK -63.806m; operating expenses were SEK 100.802m vs SEK 114.146m.
Q3 gross margin before depreciation on intangible assets was 74.0% vs 61.2%; excluding net US customs-duty effects, it was 73.2%.
Outlook and guidance
Positive cash flow remains targeted within Q4 2026, supported by sensor growth, improved margins, cost control and working-capital management.
Long-term gross margin ambition is above 70%; management cited challenges in meeting ambitious full-year sales growth targets.
Philips and other OEM partnerships are intended to become a second growth engine, with an ambition for OEM revenue to eventually exceed half of total revenue.
Latest events from Senzime
- Sensor sales up 48% and gross margin at 65.7%, with Q4 profitability on track.SEZI
Q2 2026 - Margins and cash flow improved, with strong sensor sales and major US contracts secured.SEZI
Q1 2026 - Net sales grew over 90% and adjusted EBITDA improved 16%, with profitability targeted for 2026.SEZI
Q4 2025 - Advanced nerve monitoring is revolutionizing anesthesia safety and driving rapid global growth.SEZI
Life Science Summit 2025 - 80% revenue growth, improved EBITDA, and major US contracts drive strong expansion.SEZI
Q3 2025 - Q3 sales up 90% year-over-year, driven by sensor demand and US and Asia growth.SEZI
Q3 2024 - Q2 sales up 76% year-over-year, driven by US growth and major new hospital contracts.SEZI
Q2 2024 - Q1 2025 delivered 94% sales growth, margin gains, and major US and EU hospital wins.SEZI
Q1 2025 - 2024 sales up 65%, next-gen TetraGraph launched, 2025 revenue set to double.SEZI
Q4 2024